Allergy Therapeutics gets trial go-ahead in Spain

Specialty pharmaceutical company Allergy Therapeutics announced on Tuesday that its Phase I clinical study investigating the safety and tolerability of Acarovac MPL received ‘Clinical Trial Application’ approval in Spain.

The AIM-traded firm said it now expected the formulation to begin Phase I studies immediately, to assess the safety and tolerability of two different dose regimens.

Both treatment regimens would include a two-to-four week initial updosing phase but differ in the duration of the later maintenance phase.

The Phase I trial of 32 patients is expected to last one year, the board said, and would be delivered on-time in-line with the company's stated strategic plan when funding the programme in November 2015.

If the Phase I trial is successful, the Allergy Therapeutics said it expected to launch Acarovac MPL in Spain on a named-patient basis.

“By using the successful biodegradable adjuvant system of MCT and MPL, integral in our seasonal marketed vaccines, in a perennial house dust mite vaccine, we aim to improve both safety and efficacy for the thousands of patients who suffer year-round due to house dust mite allergy,” said CEO Manuel Llobet.

“Acarovac Quattro will provide convenience to our patients and doctors and more efficient pharmacoeconomics.

“Effectively, the dosing regime in Acarovac Quattro has the potential to improve the convenience, adherence and compliance that is essential for a successful treatment, and builds on the acceptance of the existing Acarovac Plus platform.”